Compare CMRE & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | BCRX |
|---|---|---|
| Founded | 1974 | 1986 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2010 | 1994 |
| Metric | CMRE | BCRX |
|---|---|---|
| Price | $15.32 | $7.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $12.00 | ★ $20.08 |
| AVG Volume (30 Days) | 489.7K | ★ 4.0M |
| Earning Date | 02-04-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $2,085,335,000.00 | $599,816,000.00 |
| Revenue This Year | N/A | $40.20 |
| Revenue Next Year | N/A | $7.71 |
| P/E Ratio | $6.09 | ★ N/A |
| Revenue Growth | ★ 79.87 | 45.38 |
| 52 Week Low | $6.63 | $6.00 |
| 52 Week High | $16.40 | $11.31 |
| Indicator | CMRE | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 47.18 |
| Support Level | $15.02 | $7.11 |
| Resistance Level | $15.88 | $7.92 |
| Average True Range (ATR) | 0.39 | 0.36 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 24.64 | 20.78 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.